Pharmacological and technological innovations will lead to rapid improvements in medicinal products. Digitalisation, in particular, will bring about a fundamental change in the way medicines are developed and used, enabling new approaches to be adopted in research. These will create great potential for medical progress and benefits for patients. A concerted effort by all players is needed in order to implement this potential.
3 Questions to Leila Schwery-Bou-Diab, Chair Innovation Hub Committee Interpharma, VP Manufacturing & Technical Operations Janssen, Johnson & Johnson
3 Questions to Colleen Kamrad - Vice President and General Manager of GSK Switzerland
3 Questions to Urs Vögeli - Managing Director Janssen Switzerland, VP Johnson & Johnson Switzerland
Interpharma, the association of Switzerland’s research-based pharmaceutical industry, was founded in Basel in 1933.
Interpharma informs the public about issues that are important to the research-based pharmaceutical industry in Switzerland, including the pharma market in Switzerland, healthcare and biomedical research.
Information on our key figures and activities in the financial year 2020
More about the tasks and overriding aims of Interpharma
Latest information and media contacts for media representatives